comparemela.com

Latest Breaking News On - Celcuity inc view - Page 2 : comparemela.com

Celcuity Inc : Celcuity to Present Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023

MINNEAPOLIS, MN / ACCESSWIRE / March 15, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced publication

United statesDennis riedlVicky hahneRobert uhlBrian sullivanExchange commission onCelcuity incCelcuity inc viewAmerican associationCancer researchChief executive officerNovel antitumor agentsProteasome inhibitorsPoster sectionBoard numberRisk factors

Celcuity Inc Schedules Release of Fourth Quarter and Full Year 2022 Financial Results and Webcast/Conference Call

MINNEAPOLIS, MN / ACCESSWIRE / March 16, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that it will

Dennis riedlVicky hahneRobert uhlBrian sullivanCelcuity incCelcuity inc viewConference call information

Celcuity Inc : Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Patients with Advanced Breast Cancer at the 2022 San Antonio Breast Cancer Symposium

High response rates and encouraging median progression free survival rates were observed in patients regardless of PIK3CA mutation statusMedian progression free survival (PFS) of 42.3 months was reported

Vicky hahneKostenloser wertpapierhandelRobert uhlBrian sullivanExchange commission onCelcuity incCelcuity inc viewSpotlight poster discussionAntonio breast cancer symposiumChief executive officerStudy designEscalation armExpansion armRisk factorsQuarterly reportExchange commission

Celcuity Inc : Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib for the Treatment of HR+/HER2- Advanced Breast Cancer

First patient dosing enables closing of $100 million PIPE financing and drawdown of $20 million term loan trancheMINNEAPOLIS, MN / ACCESSWIRE / December 7, 2022 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage

Sara hurvitzVicky hahneKostenloser wertpapierhandelRobert uhlBrian sullivanIgor gorbatchevskyExchange commission onCompany current reports on formDavid geffen school of medicineDrug administrationCelcuity inc viewEnterprise associatesCelcuity incMedical officerDavid geffen schoolBreakthrough therapy

Celcuity Inc : Celcuity to Present Additional Data for Gedatolisib at the 2022 San Antonio Breast Cancer Symposium

MINNEAPOLIS, MN / ACCESSWIRE / November 22, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for cancer treatment, today announced

Vicky hahneKostenloser wertpapierhandelRobert wesolowskiRobert uhlBrian sullivanExchange commission onCelcuity incCelcuity inc viewSpotlight posterAntonio breast cancer symposiumSpotlight poster discussion sessionSpotlight poster discussionRisk factorsQuarterly reportExchange commission

vimarsana © 2020. All Rights Reserved.